Loading the company…
Loading the company…
Families: Incontinence, prolapse & sacral neuromodulation.
All companies · Product and company coverage
In 2025, Uromedica reported engagement with 17 surgeons and other clinicians in the states MedaRep covers, worth $212K in consulting, speaking, meals and travel for its device products, the most in Kansas ($127K to 1). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Kansas ($127K, 1 engaged), Florida ($42K, 2 engaged), Georgia ($14K, 1 engaged), New York ($7,603, 2 engaged), Nebraska ($7,500, 1 engaged).
In the last ten years FDA made 5 decisions for Uromedica (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (2). The latest was on 2026-02-11.
| Family | Decisions on record |
|---|---|
| Incontinence, prolapse & sacral neuromodulation | 7 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-02-11 | PMA | P130018-S006 | ProACT Adjustable Continence Therapy for Men · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2026-01-28 | PMA | P130018-S005 | ProACT Adjustable Continence Therapy for Men · Labeling Change - Indications/instructions/shelf life/tradename |
| 2025-10-03 | PMA | P130018-S004 | ProACT Adjustable Continence Therapy for Men · Postapproval Study Protocol |
| 2025-05-20 | PMA | P130018-S003 | ProACT Adjustable Continence Therapy for Men · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2021-06-10 | PMA | P130018-S002 | ProACT Adjustable Continence Therapy for Men · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Uromedica.